Literature DB >> 27510244

An integrated community TB-HIV adherence model provides an alternative to DOT for tuberculosis patients in Cape Town.

R Kaplan1, J Caldwell2, S Hermans3, S Adriaanse2, L Mtwisha1, L-G Bekker4, K Jennings2, R Wood4.   

Abstract

SETTING: Cape Town, South Africa.
OBJECTIVE: To evaluate anti-tuberculosis treatment outcomes and rate of antiretroviral therapy (ART) initiation using weekly community-based adherence support compared to daily directly observed therapy (DOT).
METHODS: This was a retrospective analysis comparing two cohorts treated for tuberculosis (TB) in 70 TB clinics during 6-month periods before and after the introduction of a new adherence model comprising treatment literacy sessions during 2 weeks of DOT, followed by weekly home visits by community care workers to eligible patients managing their own treatment. Odds ratios (ORs) of treatment success and ART initiation were calculated using multivariable random effects logistic regression models. Hazard ratios (HRs) of default and death were calculated using multivariable random effects Cox regression models.
RESULTS: The pre-intervention cohort comprised 11 896 patients with TB and the post-intervention cohort 11 314. There was no difference in pre- and post-intervention anti-tuberculosis treatment success rates (respectively 82.8% and 82.5%, adjusted OR [aOR] 1.02, 95%CI 0.89-1.17, P = 0.76) nor an increased hazard of death (adjusted HR [aHR] 0.98, 95%CI 0.80-1.21, P = 0.87) or default (aHR 0.97, 95%CI 0.81-1.15, P = 0.69). The ART initiation rate increased from 67% to 74% (aOR 1.43; 95%CI 1.01-1.85, P < 0.01).
CONCLUSION: Weekly community-based adherence support was a viable alternative to daily DOT, with no deterioration in anti-tuberculosis treatment outcomes and an increase in ART initiation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27510244     DOI: 10.5588/ijtld.15.0855

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  Acceptability, feasibility, and impact of a pilot tuberculosis literacy and treatment counselling intervention: a mixed methods study.

Authors:  Stephanie Law; Boitumelo Seepamore; Olivia Oxlade; Nondumiso Sikhakhane; Halima Dawood; Sheldon Chetty; Nesri Padayatchi; Dick Menzies; Amrita Daftary
Journal:  BMC Infect Dis       Date:  2021-05-18       Impact factor: 3.090

2.  DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.

Authors:  Erika Mohr; Johnny Daniels; Busisiwe Beko; Petros Isaakidis; Vivian Cox; Sarah Jane Steele; Odelia Muller; Leigh Snyman; Virginia De Azevedo; Amir Shroufi; Laura Trivino Duran; Jennifer Hughes
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

3.  "Life continues": Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa.

Authors:  Erika Mohr; Leigh Snyman; Zodwa Mbakaz; Judy Caldwell; Virginia DeAzevedo; Yulene Kock; Laura Trivino Duran; Emilie Venables
Journal:  PLoS One       Date:  2018-09-14       Impact factor: 3.240

4.  HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town.

Authors:  Pancho Mulongeni; Sabine Hermans; Judy Caldwell; Linda-Gail Bekker; Robin Wood; Richard Kaplan
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

5.  Interventions to improve linkage along the HIV-tuberculosis care cascades in low- and middle-income countries: A systematic review and meta-analysis.

Authors:  Angela Salomon; Stephanie Law; Cheryl Johnson; Annabel Baddeley; Ajay Rangaraj; Satvinder Singh; Amrita Daftary
Journal:  PLoS One       Date:  2022-05-12       Impact factor: 3.752

6.  Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.

Authors:  Tsegahun Manyazewal; Yimtubezinash Woldeamanuel; David P Holland; Abebaw Fekadu; Henry M Blumberg; Vincent C Marconi
Journal:  Trials       Date:  2020-05-05       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.